404 related articles for article (PubMed ID: 34942138)
21. Efficacy and safety of linaclotide in treating functional constipation in paediatric patients: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.
Di Lorenzo C; Khlevner J; Rodriguez-Araujo G; Xie W; Huh SY; Ando M; Hyams JS; Nurko S; Benninga MA; Simon M; Hewson ME; Saps M
Lancet Gastroenterol Hepatol; 2024 Mar; 9(3):238-250. PubMed ID: 38211604
[TBL] [Abstract][Full Text] [Related]
22. Sodium Oxybate for Excessive Daytime Sleepiness and Sleep Disturbance in Parkinson Disease: A Randomized Clinical Trial.
Büchele F; Hackius M; Schreglmann SR; Omlor W; Werth E; Maric A; Imbach LL; Hägele-Link S; Waldvogel D; Baumann CR
JAMA Neurol; 2018 Jan; 75(1):114-118. PubMed ID: 29114733
[TBL] [Abstract][Full Text] [Related]
23. Epitope-specific immunotherapy targeting CD4-positive T cells in coeliac disease: two randomised, double-blind, placebo-controlled phase 1 studies.
Goel G; King T; Daveson AJ; Andrews JM; Krishnarajah J; Krause R; Brown GJE; Fogel R; Barish CF; Epstein R; Kinney TP; Miner PB; Tye-Din JA; Girardin A; Taavela J; Popp A; Sidney J; Mäki M; Goldstein KE; Griffin PH; Wang S; Dzuris JL; Williams LJ; Sette A; Xavier RJ; Sollid LM; Jabri B; Anderson RP
Lancet Gastroenterol Hepatol; 2017 Jul; 2(7):479-493. PubMed ID: 28506538
[TBL] [Abstract][Full Text] [Related]
24. Once-nightly sodium oxybate (FT218) demonstrated improvement of symptoms in a phase 3 randomized clinical trial in patients with narcolepsy.
Kushida CA; Shapiro CM; Roth T; Thorpy MJ; Corser BC; Ajayi AO; Rosenberg R; Roy A; Seiden D; Dubow J; Dauvilliers Y
Sleep; 2022 Jun; 45(6):. PubMed ID: 34358324
[TBL] [Abstract][Full Text] [Related]
25. Medications for daytime sleepiness in individuals with idiopathic hypersomnia.
Trotti LM; Becker LA; Friederich Murray C; Hoque R
Cochrane Database Syst Rev; 2021 May; 5(5):CD012714. PubMed ID: 34031871
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of modafinil in patients with idiopathic hypersomnia without long sleep time: a multicenter, randomized, double-blind, placebo-controlled, parallel-group comparison study.
Inoue Y; Tabata T; Tsukimori N
Sleep Med; 2021 Apr; 80():315-321. PubMed ID: 33631500
[TBL] [Abstract][Full Text] [Related]
27. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial.
Grainger JD; Locatelli F; Chotsampancharoen T; Donyush E; Pongtanakul B; Komvilaisak P; Sosothikul D; Drelichman G; Sirachainan N; Holzhauer S; Lebedev V; Lemons R; Pospisilova D; Ramenghi U; Bussel JB; Bakshi KK; Iyengar M; Chan GW; Chagin KD; Theodore D; Marcello LM; Bailey CK
Lancet; 2015 Oct; 386(10004):1649-58. PubMed ID: 26231455
[TBL] [Abstract][Full Text] [Related]
28. A novel formulation of inhaled sodium cromoglicate (PA101) in idiopathic pulmonary fibrosis and chronic cough: a randomised, double-blind, proof-of-concept, phase 2 trial.
Birring SS; Wijsenbeek MS; Agrawal S; van den Berg JWK; Stone H; Maher TM; Tutuncu A; Morice AH
Lancet Respir Med; 2017 Oct; 5(10):806-815. PubMed ID: 28923239
[TBL] [Abstract][Full Text] [Related]
29. Tasimelteon for non-24-hour sleep-wake disorder in totally blind people (SET and RESET): two multicentre, randomised, double-masked, placebo-controlled phase 3 trials.
Lockley SW; Dressman MA; Licamele L; Xiao C; Fisher DM; Flynn-Evans EE; Hull JT; Torres R; Lavedan C; Polymeropoulos MH
Lancet; 2015 Oct; 386(10005):1754-64. PubMed ID: 26466871
[TBL] [Abstract][Full Text] [Related]
30. Incidence and duration of common, early-onset adverse events occurring during 2 randomized, placebo-controlled, phase 3 studies of sodium oxybate in participants with narcolepsy.
Husain AM; Bujanover S; Ryan R; Scheckner B; Black J; Profant J
J Clin Sleep Med; 2020 Sep; 16(9):1469-1474. PubMed ID: 32356515
[TBL] [Abstract][Full Text] [Related]
31. Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials.
Mignot E; Mayleben D; Fietze I; Leger D; Zammit G; Bassetti CLA; Pain S; Kinter DS; Roth T;
Lancet Neurol; 2022 Feb; 21(2):125-139. PubMed ID: 35065036
[TBL] [Abstract][Full Text] [Related]
32. Long-term study of the safety and maintenance of efficacy of solriamfetol (JZP-110) in the treatment of excessive sleepiness in participants with narcolepsy or obstructive sleep apnea.
Malhotra A; Shapiro C; Pepin JL; Hedner J; Ahmed M; Foldvary-Schaefer N; Strollo PJ; Mayer G; Sarmiento K; Baladi M; Chandler P; Lee L; Schwab R
Sleep; 2020 Feb; 43(2):. PubMed ID: 31691827
[TBL] [Abstract][Full Text] [Related]
33. Benefits and risk of sodium oxybate in idiopathic hypersomnia versus narcolepsy type 1: a chart review.
Leu-Semenescu S; Louis P; Arnulf I
Sleep Med; 2016 Jan; 17():38-44. PubMed ID: 26847972
[TBL] [Abstract][Full Text] [Related]
34. Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial.
Dauvilliers Y; Bassetti C; Lammers GJ; Arnulf I; Mayer G; Rodenbeck A; Lehert P; Ding CL; Lecomte JM; Schwartz JC;
Lancet Neurol; 2013 Nov; 12(11):1068-75. PubMed ID: 24107292
[TBL] [Abstract][Full Text] [Related]
35. A randomized, double blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy.
Sleep; 2002 Feb; 25(1):42-9. PubMed ID: 11833860
[TBL] [Abstract][Full Text] [Related]
36. Benralizumab for eosinophilic gastritis: a single-site, randomised, double-blind, placebo-controlled, phase 2 trial.
Kliewer KL; Murray-Petzold C; Collins MH; Abonia JP; Bolton SM; DiTommaso LA; Martin LJ; Zhang X; Mukkada VA; Putnam PE; Kellner ES; Devonshire AL; Schwartz JT; Kunnathur VA; Rosenberg CE; Lyles JL; Shoda T; Klion AD; Rothenberg ME
Lancet Gastroenterol Hepatol; 2023 Sep; 8(9):803-815. PubMed ID: 37336228
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of once-nightly sodium oxybate (FT218) in narcolepsy type 1 and type 2: post hoc analysis from the Phase 3 REST-ON Trial.
Dauvilliers Y; Roth T; Bogan R; Thorpy MJ; Morse AM; Roy A; Dubow J; Gudeman J
Sleep; 2023 Nov; 46(11):. PubMed ID: 37246913
[TBL] [Abstract][Full Text] [Related]
38. Safety and efficacy of laquinimod for Huntington's disease (LEGATO-HD): a multicentre, randomised, double-blind, placebo-controlled, phase 2 study.
Reilmann R; Anderson KE; Feigin A; Tabrizi SJ; Leavitt BR; Stout JC; Piccini P; Schubert R; Loupe P; Wickenberg A; Borowsky B; Rynkowski G; Volkinshtein R; Li T; Savola JM; Hayden M; Gordon MF;
Lancet Neurol; 2024 Mar; 23(3):243-255. PubMed ID: 38280392
[TBL] [Abstract][Full Text] [Related]
39. Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial.
Katzenschlager R; Poewe W; Rascol O; Trenkwalder C; Deuschl G; Chaudhuri KR; Henriksen T; van Laar T; Spivey K; Vel S; Staines H; Lees A
Lancet Neurol; 2018 Sep; 17(9):749-759. PubMed ID: 30055903
[TBL] [Abstract][Full Text] [Related]
40. Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial.
Chitnis T; Banwell B; Kappos L; Arnold DL; Gücüyener K; Deiva K; Skripchenko N; Cui LY; Saubadu S; Hu W; Benamor M; Le-Halpere A; Truffinet P; Tardieu M;
Lancet Neurol; 2021 Dec; 20(12):1001-1011. PubMed ID: 34800398
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
